KineMed (Berkeley) Reports Clinical Data on Novel Method for Identifying and Verifying Biomarker Candidates in Cerebral Spinal Fluid for Parkinson’s Disease to the Michael J. Fox Foundation (11/30/2010)

KineMed Inc. is a biotechnology company developing a platform of translatable metrics revealing the activity of key Causal Pathways in diseases. One of the company’s co-founders is Marc K. Hellerstein, M.D., Ph.D. who is on the faculty of UC Berkeley as well as serving as the Chairman of the KineMed’s Scientific Advisory Board.

From the company’s press release:
KineMed Inc. presented data on new cerebrospinal fluid (CSF) biomarkers reflecting altered brain chemistry, specifically microtubule-mediated neuronal transport of vesicular cargo molecules in Parkinson’s disease, a debilitating neurological condition with considerable unmet therapeutic needs. These biomarkers have uses for monitoring of disease progression and advancement of therapeutic interventions in Parkinson’s disease and other neurodegenerative disorders. read full press release

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: